Eli Lilly Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,071

+1.4%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (480)	1/29/1999 8:48:00 AM
From: Anthony Wong	Read Replies (1) of 642

Comments on LLY's earnings from labpuppy.com: Eli Lilly (LLY) reported $0.50 versus street expectations of $0.51 for the quarter. During the conference call, the company mentioned that it is comfortable with analyst expectations for 1999. The company announced a $1 billion share repurchase program. Prozac sales rose by only 8% but the company's newer products (such as Zyprexa, Evista, Gemzar, Reopro, etc.) performed better. The company is trying to expand its Prozac franchise through once-a-week formulations, a deal with Sepracor (SEPR) for an ‘improved" version of Prozac, combining Prozac with Zyprexa, etc. An interesting tidbit is that the preliminary safety data on its new diabetes drug, Actos (developed by Takedo) looks promising. This product will eventually compete with Warner-Lambert's (WLA) Rezulin. labpuppy.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next